Preview Mode Links will not work in preview mode

This Week in Cardiology

Jun 17, 2022

Statin Intolerance, external validity of trials, contrast shortage, and expansion of cardiology into diabetes and nephrology are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I - Statin Intolerance

- New National Lipid Association Statement on Statin Intolerance

- What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.

- Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care.

- Role of Blinding in N-of-1 Trials

- N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

II - External Validity

- Is Paxlovid, the Covid Pill, Reaching Those Who Most Need It? The Government Won't Say

- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

- PFE Press Release on EPIC SR

III - Contrast Shortage

- Global Contrast Media Shortage Blamed on COVID Lockdown in China

IV - Cardiology Expands

- Experts Elevate New Drugs for Diabetic Kidney Disease

- SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis

- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact